|
Dr. Martin E. Sanders joined Dynavax in February 2008 as Executive Vice President and Chief Development Officer. Sanders directs Dynavax's product development programs, including pre-clinical, process development, clinical, and regulatory activities. Dr. Sanders was previously with Palingen, Inc., an early clinical-stage biopharmaceutical company, where he served as President and Chief Executive Officer from 2004 to 2008. He also was a Venture Partner and Partner at Charter Life Sciences, a healthcare venture capital firm based in Palo Alto, CA during that same period of time. For the last 15 years, Dr. Sanders has consulted for approximately 50 leading pharmaceutical and biotechnology companies, including Genentech, Amgen, BiogenIDEC, Elan, and Centocor, on many key programs, nine of which have led to product approvals by the U.S. Food and Drug Administration. He received a BA in microbiology from the University of Missouri and an MD from the University of Chicago. He served as an intern and resident in Internal Medicine at Barnes Hospital, Washington University Medical Center. Dr. Sanders was a Medical Staff Fellow at the National Institute of Allergy and Infectious Diseases and at the National Cancer Institute where he made major basic research contributions in leukocyte adhesion mechanisms and immunologic memory. He also was a rheumatology fellow at the Johns Hopkins Medical School. He holds American Board Certifications in Internal Medicine, Allergy & Clinical Immunology, and Rheumatology.
| 